|VSTM2L is a promising therapeutic target and a prognostic soluble-biomarker in cholangiocarcinoma
|Jungwhoi Lee 1,* (RESEARCH PROFESSOR), Woogwang Sim2 (PI), Jungsul Lee3 (PI), Jae-Hoon Kim1 (Doctor)
|1Department of Biotechnology, Jeju National University,
2Department of Anatomy, University of California San Francisco,
3Department of Bio and Brain Engineering, KAIST
Background The aim of the present study is to provide a rational background for silencing the V-set and transmembrane domain containing 2 like (VSTM2L) in consort with recognising soluble VSTM2L against cholangiocarcinoma.
Methods A therapeutic target against cholangiocarcinoma was selected using iterative patient partitioning (IPP) calculation, and it was verified by in vitro and in silico analyses.
Results VSTM2L was selected as a potential therapeutic target against cholangiocarcinoma. Silencing the VSTM2L expression significantly attenuated the viability and survival of cholangiocarcinoma cells through blockade of the intracellular signalling pathway. In silico analysis showed that VSTM2L affected the positive regulation of cell growth in cholangiocarcinoma. Liptak’s z value revealed that the expression of VSTM2L worsened the prognosis of cholangiocarcinoma patients. In addition, soluble VSTM2L was significantly detected in the whole blood of cholangiocarcinoma patients compared with that of healthy donors.
Conclusions Our report reveals that VSTM2L might be the potential therapeutic target and a soluble prognostic biomarker against cholangiocarcinoma.
|Abstract, Accepted Manuscript [Submitted on October 25, 2023, Accepted on January 12, 2024]